Capital World Investors Boosts Holdings in Catalent, Inc. (NYSE:CTLT)

Capital World Investors boosted its holdings in Catalent, Inc. (NYSE:CTLT) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,079,994 shares of the company’s stock after buying an additional 1,098,474 shares during the quarter. Capital World Investors owned 10.56% of Catalent worth $857,264,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CTLT. Gladius Capital Management LP bought a new position in shares of Catalent during the 3rd quarter valued at approximately $28,000. GAMMA Investing LLC bought a new position in Catalent in the 4th quarter worth approximately $33,000. Cary Street Partners Investment Advisory LLC boosted its stake in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after purchasing an additional 709 shares during the period. Rakuten Securities Inc. bought a new position in Catalent in the 4th quarter worth approximately $46,000. Finally, Federated Hermes Inc. bought a new position in Catalent in the 4th quarter worth approximately $46,000.

Catalent Trading Up 0.9 %

CTLT stock traded up $0.51 during mid-day trading on Wednesday, reaching $55.47. 1,923,053 shares of the stock traded hands, compared to its average volume of 2,326,761. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent, Inc. has a one year low of $31.80 and a one year high of $60.20. The stock has a market capitalization of $10.04 billion, a PE ratio of -9.01, a PEG ratio of 5.82 and a beta of 1.20. The business has a 50-day moving average price of $55.76 and a two-hundred day moving average price of $51.82.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Equities research analysts expect that Catalent, Inc. will post 0.31 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on CTLT. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Stephens reaffirmed an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. StockNews.com began coverage on shares of Catalent in a research note on Wednesday, May 29th. They set a “sell” rating on the stock. Finally, UBS Group reaffirmed a “neutral” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Catalent presently has a consensus rating of “Hold” and an average price target of $53.14.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.